Tazorac

Tazorac is a brand name of tazarotene topical, approved by the FDA in the following formulation(s):

TAZORAC (tazarotene - cream; topical)

• 
  Manufacturer: ALLERGAN
  
  Approval date: September 29, 2000
  
  Strength(s): 0.05% ^[RLD], 0.1% ^[RLD]

TAZORAC (tazarotene - gel; topical)

• 
  Manufacturer: ALLERGAN
  
  Approval date: June 13, 1997
  
  Strength(s): 0.05% ^[RLD], 0.1% ^[RLD]

Has a generic version of Tazorac been approved?

No. There is currently no therapeutically equivalent version of Tazorac available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tazorac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable gel formulation for topical treatment of skin conditions
  Patent 5,914,334
  Issued: June 22, 1999
  Inventor(s): Charu; Prakash M.
  Assignee(s): Allergan, Inc.
  The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.
  
  Patent expiration dates:
  
  
  • June 7, 2014
    
    ✓ 
    Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
  
  



• 
  Stable gel formulation for topical treatment of skin conditions
  Patent 6,258,830
  Issued: July 10, 2001
  Inventor(s): Charu; Prakash M.
  Assignee(s): Allergan Sales, Inc.
  The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.
  
  Patent expiration dates:
  
  
  • June 7, 2014
    
    ✓ 
    Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
  
  

See also...

• Tazorac Cream Consumer Information (Wolters Kluwer)
• Tazorac Gel Consumer Information (Wolters Kluwer)
• Tazorac Consumer Information (Cerner Multum)
• Tazorac Topical Advanced Consumer Information (Micromedex)
• Tazarotene Cream Consumer Information (Wolters Kluwer)
• Tazarotene Gel Consumer Information (Wolters Kluwer)
• Tazarotene topical Consumer Information (Cerner Multum)
• Tazarotene Topical Advanced Consumer Information (Micromedex)
• Tazarotene AHFS DI Monographs (ASHP)